NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. PatelLori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, Rashmi Kumar

Research output: Contribution to journalArticlepeer-review

331 Scopus citations

Abstract

These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.

Original languageEnglish
Pages (from-to)433-451
Number of pages19
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Dive into the research topics of 'NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this